Melinda Gooderham, MD

This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.

This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.

In this interview, Melinda Gooderham, MD, MSc, touches on eyebrow and eyelash regrowth data and safety findings for upadacitinib in severe alopecia areata.

Melinda Gooderham, MD, MSc, discusses new JAMA data on upadacitinib's efficacy for severe alopecia areata in adults and adolescents.

New late-breaking phase 3 data suggest zasocitinib may help reshape the oral treatment landscape for moderate-to-severe plaque psoriasis.

In her interview, Melinda Gooderham, MD, highlights the impact of recent topline findings on zasocitinib, a once-daily pill for adults with psoriasis.

Melinda Gooderham, MD, MSc, joins The Medical Sisterhood to discuss balancing mentorship, leadership, and family, as well as the empowerment of women in the medical field.

A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting.

This interview with Melinda Gooderham, MD, covers recent findings from the phase 3 ARRECTOR trial on roflumilast foam 0.3% in scalp and body psoriasis.